Señales en vivo de CYP.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 22:07):

Stats
Volumen de hoy	83 390.00
Volumen promedio	173 845
Capitalización de mercado	37.72M
EPS	$0 ( 2024-02-26 )
Próxima fecha de ganancias	( $0 ) 2024-07-23
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.33
ATR14	$0.00200 (0.95%)

Volumen Correlación

Largo: -0.04 (neutral)

Corto: -0.41 (neutral)

Signal:(55.034) Neutral

Cynata Therapeutics Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cynata Therapeutics Ltd Correlación - Moneda/Commodity

0.00
( neutral )

0.55
( weak )

0.00
( neutral )

0.69
( moderate )

Cynata Therapeutics Ltd Finanzas

Annual	2023
Ingresos:	$1.65M
Beneficio Bruto:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2023
Ingresos:	$1.65M
Beneficio Bruto:	$1.37M (83.08 %)
EPS:	$-0.0984

FY	2022
Ingresos:	$7.77M
Beneficio Bruto:	$7.49M (96.40 %)
EPS:	$-0.0380

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0590

Financial Reports:

No articles found.

Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.